18.6 C
New York
Wednesday, September 27, 2023

Investors’ Patience Is Being Tested Right Now By Bio-Rad Laboratories Inc. (NYSE: BIO)

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Bio-Rad Laboratories Inc. (BIO) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$6.74, or -1.79%, to $369.49. The Bio-Rad Laboratories Inc. has recorded 29,379 volume in the after hours trading session. Yahoo Finance discussed the stock recently as it posted Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 2023 Healthcare Conference.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Stocks Info

Bio-Rad Laboratories Inc. is listed on the NYSE as a member of the Healthcare sector and is a part of the Medical Devices industry. At the end of the last regular session, the stock closed at $376.23 and fluctuated between $384.37 as its day high and $370.93 as its day low. The current market capitalization of Bio-Rad Laboratories Inc. is $10.93B. A total of 0.53 million shares were traded on the day, compared to an average of 195.16K shares.

Insider Activity

Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, BIO has seen 0 BUY and 1 SELL insider trades, representing the acquisition of 0 and the disposition of 300 shares. Over the last 12 months, there were 6 BUYs and 13 SELLs from insiders. Insiders purchased 3,479 shares during that period but sold 4,034.

In the most recent transaction, ERNST TIMOTHY S sold 2,350 shares of BIO for 395.60 per share on Aug 30. After the transaction, the EVP, General Counsel & Sec now owns 2,416 company shares. In a previous transaction on Aug 23, ERNST TIMOTHY S sold 300 shares at 384.69 per share. BIO shares that EVP, General Counsel & Sec owns now total 2,416.

Among the insiders who sold shares, Crowley Michael disposed of 500 shares on Jun 15 at a per-share price of $379.39. This resulted in the EVP, GBL Commercial Operations holding 6,040 shares of BIO after the transaction. In another insider transaction, RAMALINGAM AJIT sold 198 shares at $368.30 per share on Jun 06. Company shares held by the SVP, Chief Accounting Officer now total 0.

Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for BIO in the last 3 months, the mean price target is $530.17 with high estimates of $560.00 and low estimates of $510.00. In terms of 52-week highs and lows, BIO has a high of $509.62 and a low of $344.63.

As of this writing, BIO has an earnings estimate of $2.84 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of $3.13 per share and a lower estimate of $2.62. The company reported an EPS of $3.34 in the last quarter, which was -5.60% lower than expectations of $3.54.

Balance Sheet Annually/Quarterly

A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. BIO’s latest balance sheet shows that the firm has $875.48M in Cash & Short Term Investments as of fiscal 2021. There were $11.00M in debt and $680.94M in liabilities at the time. Its Book Value Per Share was $287.75, while its Total Shareholder’s Equity was $13.67B.

Analysts Opinion

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BIO is Buy with a score of 4.75.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles